Literature DB >> 19946337

MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors.

P Mestdagh1, E Fredlund, F Pattyn, J H Schulte, D Muth, J Vermeulen, C Kumps, S Schlierf, K De Preter, N Van Roy, R Noguera, G Laureys, A Schramm, A Eggert, F Westermann, F Speleman, J Vandesompele.   

Abstract

Increased activity of MYC protein-family members is a common feature in many cancers. Using neuroblastoma as a tumor model, we established a microRNA (miRNA) signature for activated MYCN/c-MYC signaling in two independent primary neuroblastoma tumor cohorts and provide evidence that c-MYC and MYCN have overlapping functions. On the basis of an integrated approach including miRNA and messenger RNA (mRNA) gene expression data we show that miRNA activation contributes to widespread mRNA repression, both in c-MYC- and MYCN-activated tumors. c-MYC/MYCN-induced miRNA activation was shown to be dependent on c-MYC/MYCN promoter binding as evidenced by chromatin immunoprecipitation. Finally, we show that pathways, repressed through c-MYC/MYCN miRNA activation, are highly correlated to tumor aggressiveness and are conserved across different tumor entities suggesting that c-MYC/MYCN activate a core set of miRNAs for cooperative repression of common transcriptional programs related to disease aggressiveness. Our results uncover a widespread correlation between miRNA activation and c-MYC/MYCN-mediated coding gene expression modulation and further substantiate the overlapping functions of c-MYC and MYCN in the process of tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19946337     DOI: 10.1038/onc.2009.429

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  68 in total

1.  ALK positively regulates MYCN activity through repression of HBP1 expression.

Authors:  Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman
Journal:  Oncogene       Date:  2018-12-11       Impact factor: 9.867

2.  MYCN-mediated miR-21 overexpression enhances chemo-resistance via targeting CADM1 in tongue cancer.

Authors:  Guopei Zheng; Nan Li; Xiaoting Jia; Cong Peng; Liyun Luo; Yingen Deng; Jiang Yin; Ying Song; Hao Liu; Minying Lu; Zhijie Zhang; Yixue Gu; Zhimin He
Journal:  J Mol Med (Berl)       Date:  2016-04-08       Impact factor: 4.599

Review 3.  The role of genetic and epigenetic alterations in neuroblastoma disease pathogenesis.

Authors:  Raquel Domingo-Fernandez; Karen Watters; Olga Piskareva; Raymond L Stallings; Isabella Bray
Journal:  Pediatr Surg Int       Date:  2012-12-29       Impact factor: 1.827

4.  MiRNA-335 suppresses neuroblastoma cell invasiveness by direct targeting of multiple genes from the non-canonical TGF-β signalling pathway.

Authors:  Jennifer Lynch; Joanna Fay; Maria Meehan; Kenneth Bryan; Karen M Watters; Derek M Murphy; Raymond L Stallings
Journal:  Carcinogenesis       Date:  2012-03-01       Impact factor: 4.944

5.  miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples.

Authors:  Katleen De Preter; Pieter Mestdagh; Joëlle Vermeulen; Fjoralba Zeka; Arlene Naranjo; Isabella Bray; Victoria Castel; Caifu Chen; Elzbieta Drozynska; Angelika Eggert; Michael D Hogarty; Ewa Izycka-Swieszewska; Wendy B London; Rosa Noguera; Marta Piqueras; Kenneth Bryan; Benjamin Schowe; Peter van Sluis; Jan J Molenaar; Alexander Schramm; Johannes H Schulte; Raymond L Stallings; Rogier Versteeg; Geneviève Laureys; Nadine Van Roy; Frank Speleman; Jo Vandesompele
Journal:  Clin Cancer Res       Date:  2011-10-26       Impact factor: 12.531

6.  Pathway-based analysis of breast cancer.

Authors:  Dong Song; Miao Cui; Gang Zhao; Zhimin Fan; Katherine Nolan; Ying Yang; Peng Lee; Fei Ye; David Y Zhang
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

Review 7.  The roles of microRNAs in neuroblastoma.

Authors:  Hong Mei; Zhen-Yu Lin; Qiang-Song Tong
Journal:  World J Pediatr       Date:  2014-01-25       Impact factor: 2.764

8.  miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis.

Authors:  Li Ma; Jennifer Young; Harsha Prabhala; Elizabeth Pan; Pieter Mestdagh; Daniel Muth; Julie Teruya-Feldstein; Ferenc Reinhardt; Tamer T Onder; Scott Valastyan; Frank Westermann; Frank Speleman; Jo Vandesompele; Robert A Weinberg
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

9.  MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2.

Authors:  Niamh H Foley; Isabella M Bray; Amanda Tivnan; Kenneth Bryan; Derek M Murphy; Patrick G Buckley; Jacqueline Ryan; Anne O'Meara; Maureen O'Sullivan; Raymond L Stallings
Journal:  Mol Cancer       Date:  2010-04-21       Impact factor: 27.401

10.  Alteration of microRNAs regulated by c-Myc in Burkitt lymphoma.

Authors:  Anna Onnis; Giulia De Falco; Giuseppina Antonicelli; Monica Onorati; Cristiana Bellan; Omar Sherman; Shaheen Sayed; Lorenzo Leoncini
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.